These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 38548414)

  • 21. Comprehensive analysis of neoantigens derived from structural variation across whole genomes from 2528 tumors.
    Shi Y; Jing B; Xi R
    Genome Biol; 2023 Jul; 24(1):169. PubMed ID: 37461029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of neoantigens in tumor immunotherapy.
    Shang S; Zhao Y; Qian K; Qin Y; Zhang X; Li T; Shan L; Wei M; Xi J; Tang B
    Biomed Pharmacother; 2022 Jul; 151():113118. PubMed ID: 35623169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. pTuneos: prioritizing tumor neoantigens from next-generation sequencing data.
    Zhou C; Wei Z; Zhang Z; Zhang B; Zhu C; Chen K; Chuai G; Qu S; Xie L; Gao Y; Liu Q
    Genome Med; 2019 Oct; 11(1):67. PubMed ID: 31666118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies.
    Lo AA; Wallace A; Oreper D; Lounsbury N; Havnar C; Pechuan-Jorge X; Wu TD; Bourgon R; Jones R; Krogh K; Yang GY; Zill OA
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor neoantigens: Novel strategies for application of cancer immunotherapy.
    Guan H; Wu Y; Li LU; Yang Y; Qiu S; Zhao Z; Chu X; He J; Chen Z; Zhang Y; Ding H; Pan J; Pan Y
    Oncol Res; 2023; 31(4):437-448. PubMed ID: 37415744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sources of Cancer Neoantigens beyond Single-Nucleotide Variants.
    Capietto AH; Hoshyar R; Delamarre L
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy.
    Okada M; Shimizu K; Fujii SI
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoantigen vaccine: an emerging tumor immunotherapy.
    Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
    Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene fusion neoantigens: Emerging targets for cancer immunotherapy.
    Wang Y; Shi T; Song X; Liu B; Wei J
    Cancer Lett; 2021 May; 506():45-54. PubMed ID: 33675984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of neoantigens for individualized therapeutic cancer vaccines.
    Lang F; Schrörs B; Löwer M; Türeci Ö; Sahin U
    Nat Rev Drug Discov; 2022 Apr; 21(4):261-282. PubMed ID: 35105974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determinants for Neoantigen Identification.
    Garcia-Garijo A; Fajardo CA; Gros A
    Front Immunol; 2019; 10():1392. PubMed ID: 31293573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Seq2Neo: A Comprehensive Pipeline for Cancer Neoantigen Immunogenicity Prediction.
    Diao K; Chen J; Wu T; Wang X; Wang G; Sun X; Zhao X; Wu C; Wang J; Yao H; Gerarduzzi C; Liu XS
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer Immunotherapies Ignited by a Thorough Machine Learning-Based Selection of Neoantigens.
    Jurczak S; Druchok M
    Adv Biol (Weinh); 2024 Oct; 8(10):e2400114. PubMed ID: 38971967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
    Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
    Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ScanNeo2: a comprehensive workflow for neoantigen detection and immunogenicity prediction from diverse genomic and transcriptomic alterations.
    Schäfer RA; Guo Q; Yang R
    Bioinformatics; 2023 Nov; 39(11):. PubMed ID: 37882750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines.
    Roesler AS; Anderson KS
    Methods Mol Biol; 2022; 2410():649-670. PubMed ID: 34914074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells.
    Li J; Xiao Z; Wang D; Jia L; Nie S; Zeng X; Hu W
    Mol Cancer; 2023 Aug; 22(1):141. PubMed ID: 37649123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GNIFdb: a neoantigen intrinsic feature database for glioma.
    Li W; Sun T; Li M; He Y; Li L; Wang L; Wang H; Li J; Wen H; Liu Y; Chen Y; Fan Y; Xin B; Zhang J
    Database (Oxford); 2022 Feb; 2022():. PubMed ID: 35150127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen.
    Chen P; Chen D; Bu D; Gao J; Qin W; Deng K; Ren L; She S; Xu W; Yang Y; Xie X; Liao W; Chen H
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37076248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.